ClinicalTrials.gg
Not yet recruitingNCT06191328Updated Jan 5, 2024

A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

An interventional study of Chiglitazar sodium in Diabetes, sponsored by Yufan Wang. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Yufan Wang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.

Planned enrollment
217th of 280
40 · median 143
Started
2024
with 38 others
No phase
118 of 417
27 open now
Primary completion
2025-06
later than 27 of 116 live
Registered
303rd of 417
by date

Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 217th largest by planned enrollment of the 280 interventional ones that give a count, is one of 39 that started in 2024, is one of 118 with no phase, reaches primary completion later than 27 of the 116 other live ones, and was the 303rd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Diabetes Mellitus with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about inour study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration.

The main question[s] it aims to answer are:

  • Quantitative lipidomics information enables in-depth analysis of lipids and can reveal Chiglitazar Sodium-specific lipid metabolic patterns, thereby strengthening lipidomics as a promising tool for exploring the molecular mechanisms of T2DM.
  • It can also be applied to other T2DM lipidomics studies to better understand lipid metabolism patterns and integration with other omics measures.
Read the detailed description

Chiglitazar Sodium for lipid profile abnormalities and its associated effective lipid molecular biomarkers have never been studied in patients with T2DM. Therefore, our study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration using ultra-high performance liquid chromatography-Tandem quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). For completeness, we also evaluated the effects of Chiglitazar Sodium treatment on metabolic markers associated with T2DM and its association with lipidomic changes.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes (T2DM) WHO meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999;
  2. Male or female patients aged ≥18, ≤70 years;
  3. ≥18.5 Kg/m2, \< 35 Kg/m2;
  4. (HbA1C) ≥7.5%; ≤10.5%;
  5. Triglyceride ≤500 mg /dL (5.65 mmol/L) (if the researchers judge that the transient increase caused by diet, etc., can be repeated detection)
  6. Total cholesterol (TC) ≤250mg/dl (6.45mmol/L)
  7. T2DM patients who are taking one or two kinds of oral hypoglycemic drugs with fixed dose ≥2 months and uncontrolled blood glucose.
  8. Voluntarily sign and agree to enter the trial group.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes or other specific type of diabetes
  2. Fasting blood glucose (FPG) > 13.3 mmol/L (240 mg/dL);
  3. Triglyceride (TG) > 500 mg /dL (5.65 mmol/L);
  4. Total cholesterol (TC) > 250mg/dl (> 6.45mmol/L);
  5. hypertension [that is, on the basis of improving the lifestyle, the blood pressure is still not up to standard after 1 month of applying a reasonably tolerable amount of 3 or more antihypertensive drugs (including diuretics), or the blood pressure can be effectively controlled by taking 4 or more antihypertensive drugs;
  6. Taking fibrates, statins, thiazolidinediones, insulin drugs;
  7. A clear diagnosis of severe osteoporosis or any other known bone disease;
  8. A history of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes;
  9. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio > 300 mg/g; Marked peripheral neuropathy, etc.);
  10. The (NYHA) defines congestive heart failure as grade III or IV;
  11. Significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as > 2.5 times the and/or ALT> 2.5 times the upper limit of normal and/or total > 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (\<60 ml/ (min*1.73m2));
  12. Pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate ;
  13. Participating in a clinical trial of another drug or medical device in or within 3 months prior to screening;
  14. The investigator considers it inappropriate to participate in this clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Drug: Chiglitazar sodium

Interventions

  • DrugChiglitazarStudies of ChiglitazarChiglitazar pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.

06

What researchers measure

Primary outcomes

  1. HbA1c

    Change in HbA1c from baseline

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. Serum lipid profile

    Changes from baseline in sphingomyelin (SMs), ceramide (CER), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PEs), lysophosphatidylethanolamine (LPEs), and phosphatidylcholine (PC)

    Time frame: 12 weeks of treatment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jun 2025, 16 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartEst.
Jan 31, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06191328
Lead sponsor
Yufan Wang
Responsible party
Yufan Wang (Professor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
Jan 5, 2024
Start date
Jan 31, 2024 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jan 5, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion